{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:08:04Z","timestamp":1791529684750,"version":"4.3.4"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,3,3]],"date-time":"2010-03-03T00:00:00Z","timestamp":1267574400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1590\/s1807-59322010000200015","type":"journal-article","created":{"date-parts":[[2010,3,11]],"date-time":"2010-03-11T08:41:56Z","timestamp":1268296916000},"page":"221-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update"],"prefix":"10.1016","volume":"65","author":[{"given":"Cansel","family":"Turkay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benan","family":"Kasapoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1590\/S1807-59322010000200015_bib1","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.addr.2007.07.003","article-title":"Mouse models of inflammatory bowel disease","volume":"59","author":"Wirtz","year":"2007","journal-title":"Adv. Drug Deliv Rev"},{"key":"10.1590\/S1807-59322010000200015_bib2","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/gut.52.10.1432","article-title":"Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990\u20132001","volume":"52","author":"Hildebrand","year":"2003","journal-title":"Gut"},{"key":"10.1590\/S1807-59322010000200015_bib3","first-page":"123","article-title":"The Diagnosis and Treatment of Crohn\u2019s Disease and Ulcerative Colitis","volume":"106","author":"Baumgart","year":"2009","journal-title":"Dtsch Arztebl Int"},{"key":"10.1590\/S1807-59322010000200015_bib4","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/jcp.2003.015214","article-title":"Indeterminate colitis","volume":"57","author":"Guindi","year":"2004","journal-title":"J. Clin Pathol"},{"key":"10.1590\/S1807-59322010000200015_bib5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1053\/j.gastro.2007.09.001","article-title":"Diagnostics of inflammatory bowel disease","volume":"133","author":"Nikolaus","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1590\/S1807-59322010000200015_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2007.01556.x","article-title":"Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMNelastase, CRP, and clinical indices","volume":"103","author":"Langhorst","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ibd.20096","article-title":"Genetics of the innate immune response in inflammatory bowel disease","volume":"13","author":"Van Limbergen","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1590\/S1807-59322010000200015_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11894-007-0065-5","article-title":"Current and future diagnostic approaches: from serologies to imaging","volume":"9","author":"Bruining","year":"2007","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1590\/S1807-59322010000200015_bib9","first-page":"5115","article-title":"New serological biomarkers of inflammatory bowel disease, World J","volume":"14","author":"Li","year":"2008","journal-title":"Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.gtc.2008.03.001","article-title":"(Auto) antibodies in inflammatory bowel diseases","volume":"37","author":"Vermeire","year":"2008","journal-title":"Gastroenterol. Clin. North Am"},{"key":"10.1590\/S1807-59322010000200015_bib11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.immunol.20.100301.064816","article-title":"The immunology of mucosal models of inflammation","volume":"20","author":"Strober","year":"2002","journal-title":"Annu. Rev Immunol"},{"key":"10.1590\/S1807-59322010000200015_bib12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ibd.20146","article-title":"Seroreactivity to microbial components in Crohn\u2019s disease is associated with ileal involvement, noninflammatory disease behavior and NOD2\/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients","volume":"13","author":"Papp","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1590\/S1807-59322010000200015_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1572-0241.2007.01652.x","article-title":"New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2\/CARD15 genotype in a Hungarian IBD cohort","volume":"103","author":"Papp","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib14","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/ibd.20226","article-title":"IBD serological panels: facts and perspectives","volume":"13","author":"Peyrin-Biroulet","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1590\/S1807-59322010000200015_bib15","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/gut.2006.108043","article-title":"New serological markers in inflammatory bowel disease are associated with complicated disease behaviour","volume":"56","author":"Ferrante","year":"2007","journal-title":"Gut"},{"key":"10.1590\/S1807-59322010000200015_bib16","article-title":"Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn\u2019s disease","author":"Joossens","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1590\/S1807-59322010000200015_bib17","first-page":"162","article-title":"Clinical utility of serological markers in inflammatory bowel disease","volume":"56","author":"Mokrowiecka","year":"2009","journal-title":"Hepatogastroenterology"},{"key":"10.1590\/S1807-59322010000200015_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1155\/2008\/974540","article-title":"Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn\u2019s disease and ulcerative colitis","volume":"22","author":"Anand","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MPG.0b013e318183e112","article-title":"Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease","volume":"48","author":"Russell","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1590\/S1807-59322010000200015_bib20","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2009.79","article-title":"Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype","volume":"104","author":"Seow","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib21","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1074\/mcp.M800593-MCP200","article-title":"Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip","volume":"8","author":"Chen","year":"2009","journal-title":"Mol Cell Proteomics"},{"key":"10.1590\/S1807-59322010000200015_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s005350300020","article-title":"Anti- Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value","volume":"38","author":"Hisabe","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib23","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1572-0241.2004.40486.x","article-title":"A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients","volume":"99","author":"Lawrance","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"10.1590\/S1807-59322010000200015_bib24","first-page":"S262","article-title":"Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis","volume":"23","author":"Osada","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1590\/S1807-59322010000200015_bib25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","article-title":"Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease","volume":"11","author":"Solem","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1590\/S1807-59322010000200015_bib26","first-page":"313","article-title":"Comparative usefulness of erythrocyte sedimentation rate and C-reactive protein in assessing the severity of ulcerative colitis","volume":"48","author":"Ha","year":"2006","journal-title":"Korean J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00005-009-0031-z","article-title":"Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients","volume":"57","author":"Szkaradkiewicz","year":"2009","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1590\/S1807-59322010000200015_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1365-2036.2002.01196.x","article-title":"Review article: faecal markers in the assessment of activity in inflammatory bowel disease","volume":"16","author":"Poullis","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1590\/S1807-59322010000200015_bib29","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0016-5085(83)80015-8","article-title":"Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn\u2019s disease","volume":"85","author":"Saverymuttu","year":"1983","journal-title":"Gastroenterology"},{"key":"10.1590\/S1807-59322010000200015_bib30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/gut.24.8.718","article-title":"Alpha 1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn\u2019s disease","volume":"24","author":"Karbach","year":"1983","journal-title":"Gut"},{"key":"10.1590\/S1807-59322010000200015_bib31","first-page":"2309","article-title":"Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn\u2019s disease but not in ulcerative colitis","volume":"46","author":"Becker","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1590\/S1807-59322010000200015_bib32","first-page":"597","article-title":"Fecal excretion of alpha 2 macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease","volume":"37","author":"Becker","year":"1999","journal-title":"Z Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib33","series-title":"Activity Related Abnormalities in Inflammatory Bowel Disease","first-page":"89","article-title":"Significance of faecal lysozme excretion and alph-1-antitrypsin clearance in the assessment of activity of inflammatory bowel disease","author":"Crama-Bohbouth","year":"1998"},{"key":"10.1590\/S1807-59322010000200015_bib34","first-page":"117","article-title":"Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome","volume":"51","author":"Silberer","year":"2005","journal-title":"Clin Lab"},{"key":"10.1590\/S1807-59322010000200015_bib35","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/01.MIB.0000187980.08686.18","article-title":"Comparison of 4 neutrophilderive proteins in feces as indicators of disease activity in ulcerative colitis","volume":"11","author":"Langhorst","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1590\/S1807-59322010000200015_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2739\/kurumemedj.45.69","article-title":"Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease","volume":"45","author":"Saiki","year":"1998","journal-title":"Kurume Med J"},{"key":"10.1590\/S1807-59322010000200015_bib37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/cs0920307","article-title":"Differential excretion of leucocyte granule components in inflammatory bowel disease: implications for pathogenesis","volume":"92","author":"Dwarakanath","year":"1997","journal-title":"Clin Sci"},{"key":"10.1590\/S1807-59322010000200015_bib38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/00365529209165434","article-title":"Faecal elastase reflects disease activity in active ulcerative colitis","volume":"27","author":"Adeyemi","year":"1992","journal-title":"Scand J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib39","first-page":"927","article-title":"Faecal lactoferrin as a marker of disease activity in inflammatory bowel disease: comparison with other neutrophil derived proteins","volume":"91","author":"Sugi","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib40","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1128\/jcm.30.5.1238-1242.1992","article-title":"Measurement of fecal lactoferrin as a marker of fecal leukocytes","volume":"30","author":"Guerrant","year":"1992","journal-title":"J Clin Microbiol"},{"key":"10.1590\/S1807-59322010000200015_bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cca.2007.02.025","article-title":"Enzymes in feces: useful markers of chronic inflammatory bowel disease","volume":"381","author":"Angriman","year":"2007","journal-title":"Clin Chim Acta"},{"key":"10.1590\/S1807-59322010000200015_bib42","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1080\/00365520701427094","article-title":"Relationship between fecal lactoferrin and inflammatory bowel disease","volume":"42","author":"Dai","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib43","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1572-0241.2003.07458.x","article-title":"Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation","volume":"98","author":"Kane","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ibd.20275","article-title":"Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies","volume":"14","author":"Schoepfer","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1590\/S1807-59322010000200015_bib45","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s10350-007-0303-9","article-title":"Accuracy of four fecal assays in the diagnosis of colitis","volume":"50","author":"Schoepfer","year":"2007","journal-title":"Dis Colon Rectum"},{"key":"10.1590\/S1807-59322010000200015_bib46","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0140-6736(90)93237-J","article-title":"Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin","volume":"336","author":"Steinbakk","year":"1990","journal-title":"Lancet"},{"key":"10.1590\/S1807-59322010000200015_bib47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3109\/00365529209011186","article-title":"Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study","volume":"27","author":"R\u00f8seth","year":"1992","journal-title":"Scand J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib48","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1590\/S1807-59322009000500009","article-title":"The role of fecal calprotectin in investigating inflammatory bowel diseases","volume":"64","author":"Erbayrak","year":"2009","journal-title":"Clinics"},{"key":"10.1590\/S1807-59322010000200015_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.20986","article-title":"Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes","author":"Schoepfer","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1590\/S1807-59322010000200015_bib50","doi-asserted-by":"crossref","first-page":"622","DOI":"10.20452\/pamw.506","article-title":"Clinical utility of the assessment of fecal calprotectin in Le\u03bcniowski-Crohn\u2019s disease","volume":"118","author":"Eder","year":"2008","journal-title":"Pol Arch Med Wewn"},{"key":"10.1590\/S1807-59322010000200015_bib51","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ibd.20933","article-title":"Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse","volume":"15","author":"Gisbert","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1590\/S1807-59322010000200015_bib52","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1572-0241.2008.01870.x","article-title":"Can calprotectin predict relapse risk in inflammatory bowel disease?","volume":"103","author":"D\u2019Inc\u00e0","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib53","first-page":"468","article-title":"Fecal calprotectin levels in healthy children studied with an improved assay","volume":"37","author":"Fagerberg","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1590\/S1807-59322010000200015_bib54","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/01.meg.0000230080.59135.e1","article-title":"Prophylactic aspirin therapy does not increase faecal calprotectin concentrations","volume":"18","author":"Montalto","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1590\/S1807-59322010000200015_bib55","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00535-008-2206-5","article-title":"Low-dose aspirin-induced gastrointestinal diseases: past, present, and future","volume":"43","author":"Shiotani","year":"2008","journal-title":"J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib56","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3109\/00365529309098312","article-title":"Faecal calprotectin: a novel test for the diagnosis of colorectal cancer?","volume":"28","author":"R\u00f8seth","year":"1993","journal-title":"Scand J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib57","first-page":"2683","article-title":"Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm","volume":"96","author":"Husebye","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib58","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/00365520701320513","article-title":"Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease","volume":"42","author":"Czub","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.20946","article-title":"Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders","author":"Jeffery","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1590\/S1807-59322010000200015_bib60","first-page":"96","article-title":"Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease","volume":"2","author":"Lundberg","year":"2005","journal-title":"Gastroenterol Hepatol"},{"key":"10.1590\/S1807-59322010000200015_bib61","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1542-3565(05)00182-5","article-title":"Rectal mucosal nitric oxide in differentiation of inflammatory bowel disease and irritable bowel syndrome","volume":"3","author":"Reinders","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1590\/S1807-59322010000200015_bib62","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/00365520701320505","article-title":"Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease","volume":"42","author":"Reinders","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib63","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.3748\/wjg.v12.i21.3386","article-title":"Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders","volume":"12","author":"Ljung","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib64","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/j.1572-0241.2002.05837.x","article-title":"A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease","volume":"97","author":"Peterson","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib65","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/00365510701452838","article-title":"Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis","volume":"67","author":"Peterson","year":"2007","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1590\/S1807-59322010000200015_bib66","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.3748\/wjg.14.5584","article-title":"Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease","volume":"14","author":"Wagner","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2559.1996.262309.x","article-title":"Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease","volume":"28","author":"Bischoff","year":"1996","journal-title":"Histopathology"},{"key":"10.1590\/S1807-59322010000200015_bib68","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/bjs.6593","article-title":"Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn\u2019s disease","volume":"96","author":"Lamb","year":"2009","journal-title":"Br J Surg"},{"key":"10.1590\/S1807-59322010000200015_bib69","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ibd.20535","article-title":"Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease","volume":"15","author":"Ashorn","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1590\/S1807-59322010000200015_bib70","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ibd.20376","article-title":"Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease","volume":"14","author":"Walkiewicz","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"14","key":"10.1590\/S1807-59322010000200015_bib71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3748\/wjg.14.53","article-title":"Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis","volume":"7","author":"Xiang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib72","first-page":"673","article-title":"Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis","volume":"104","author":"Ho","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1590\/S1807-59322010000200015_bib73","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1365-2036.2008.03835.x","article-title":"Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn\u2019s disease and histological findings","volume":"28","author":"Sipponen","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1590\/S1807-59322010000200015_bib74","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2007.01556.x","article-title":"Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices","volume":"103","author":"Langhorst","year":"2008","journal-title":"Am J Gastroenterol"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222024978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222024978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.scielo.br\/pdf\/clin\/v65n2\/a15v65n2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:13:40Z","timestamp":1761722020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222024978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S1807593222024978"],"URL":"https:\/\/doi.org\/10.1590\/s1807-59322010000200015","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1590\/S1807-59322010000200015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}]}}